News
Novo Nordisk (NVO) vs Eli Lilly (LLY): Who’s Winning the Weight-Loss Drug War?
Using the same discretized logic, let’s consider LLY stock. In the trailing 10 weeks, the market voted to buy LLY six times and sell four times. During this period, the security fell into a downward spiral. Based on the earlier naming logic, we’ll call this a 6-4-D sequence.
Eli Lilly’s weight-loss pill disappointed in a key trial, but CEO David Ricks and other insiders together bought nearly $3 ...
StockStory.org on MSN17h
Eli Lilly (LLY) Stock Trades Up, Here Is Why
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after reports of ...
Eli Lilly (LLY) stock recovers as company executives seize a rare buying opportunity to make a series of insider purchases ...
Last and least, I look at the drug stocks and I can’t believe how awful they really are, with now Eli Lilly last joining the ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...
Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Click here to read an analysis of ...
South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback